美国 · 经济杂志 · Quartz
Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

详细摘要
Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (qz.com)



